eyeGENE®: a vision community resource facilitating patient care and paving the path for research through molecular diagnostic testing
- 10 May 2013
- journal article
- research article
- Published by Wiley in Clinical Genetics
- Vol. 84 (2) , 190-197
Abstract
Molecular genetics and genomics are revolutionizing the study and treatment of inherited eye diseases. In recognition of the impact of molecular genetics on vision and ophthalmology, the National Eye Institute established the National Ophthalmic Disease Genotyping and Phenotyping Network (eyeGENE®) as a multidirectional research initiative whereby a clinical component for patients diagnosed with inherited eye disease fosters research into the causes and mechanisms of these ophthalmic diseases. This is accomplished by broadening access to genetic diagnostic testing and maintaining a repository of DNA samples from clinically characterized individuals and their families to allow investigations of the causes, interventions, and management of genetic eye disorders. The eyeGENE® Network currently includes Clinical Laboratory Improvement Amendments (CLIA)‐certified diagnostic laboratory partners, over 270 registered clinical organizations with 500 registered users from around the United States and Canada, and is now testing approximately 100 genes representing 35 inherited eye diseases. To date, the Network has received 4400 samples from individuals with rare inherited eye diseases, which are available for access by the vision research community. eyeGENE® is a model partnership between the U.S. federal government, eye health care providers, CLIA‐approved molecular diagnostic laboratories, private industry, and scientists who represent a broad research constituency.Keywords
This publication has 37 references indexed in Scilit:
- Allelic Heterogeneity and Genetic Modifier Loci Contribute to Clinical Variation in Males with X-Linked Retinitis Pigmentosa Due to RPGR MutationsPLOS ONE, 2011
- Cone Photoreceptor Abnormalities Correlate with Vision Loss in Patients with Stargardt DiseaseInvestigative Ophthalmology & Visual Science, 2011
- Identification of Disease-Causing Mutations in Autosomal Dominant Retinitis Pigmentosa (adRP) Using Next-Generation DNA SequencingInvestigative Ophthalmology & Visual Science, 2011
- Gene Therapy for Leber's Congenital Amaurosis is Safe and Effective Through 1.5 Years After Vector AdministrationMolecular Therapy, 2010
- Human TUBB3 Mutations Perturb Microtubule Dynamics, Kinesin Interactions, and Axon GuidanceCell, 2010
- Age-dependent effects of RPE65 gene therapy for Leber's congenital amaurosis: a phase 1 dose-escalation trialThe Lancet, 2009
- Human RPE65 Gene Therapy for Leber Congenital Amaurosis: Persistence of Early Visual Improvements and Safety at 1 YearHuman Gene Therapy, 2009
- Vision 1 Year after Gene Therapy for Leber's Congenital AmaurosisNew England Journal of Medicine, 2009
- Treatment of Leber Congenital Amaurosis Due to RPE65 Mutations by Ocular Subretinal Injection of Adeno-Associated Virus Gene Vector: Short-Term Results of a Phase I TrialHuman Gene Therapy, 2008
- Human gene therapy for RPE65 isomerase deficiency activates the retinoid cycle of vision but with slow rod kineticsProceedings of the National Academy of Sciences, 2008